Will Actavis Get Help In Namenda Suit From Doryx Product Hopping Ruling?
This article was originally published in The Pink Sheet Daily
Executive Summary
Warner Chilcott’s reformulations of Doryx are not anticompetitive, district court finds, but New York AG says its Namenda switching suit is different since there are no alternative interchangeable drugs on the market.